US › Healthcare

Kamada (KMDA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$7.34+1.52%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$45.2M

Revenue YoY

+2.8%

Net profit

$4.1M

Profit YoY

+4.2%

EPS

$0.07

EPS estimate

$0.12

Net margin

9.1%

EPS came in at 0.07 against a street estimate of 0.12 — a miss of 41.7%.

Key statistics

Market cap

$411.9M

P/E

20.4

Forward P/E

17.3

P/B

1.59

Book value

$4.50

EPS (TTM)

$0.35

Dividend yield

3.49%

52-week high

$9.07

52-week low

$6.31

50-day MA

$7.33

200-day MA

$7.71

Beta

0.15

Analyst view

Analysts rate Kamada a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $13.00.

Shareholding

Insiders

7.20%

Institutions

48.55%

Largest institutional holders

Fund	Stake
State of Tennessee, Treasury Department	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kamada — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.